CareDx

CareDx

Biotechnology
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company’s commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

$3.3B

Market Cap • 10/16/2026

1998

(28 years)

Founded

2014

(12 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

7,8

P/S

7,2

P/EBITDA

—

P/OCF

35,4

P/FCF

39,1

P/E

30,9

BVPS

8,2

EPS

—

Market Cap

Market Cap

3,3B

EV

3B

EV/Revenue

6,4

EV/EBITDA

-30,1

EV/EBIT

-25

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

1,7%

Total Yield

1,7%

Payout

0%

Retained Earnings

-505,4M

Profitability

Gross Margin

100%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

17,4%

Capex/Revenue

2%

Capex/D&A

45,2%

Capex/OCF

9,6%

SBC/OCF

39,5%

% PPE

8,1%

% Goodwill

6,7%

ROE

—

ROIC

—

Growth

CAGR Revenue 5Y

12,6%

CAGR Op. Income 5Y

59%

CAGR Net Income 5Y

66,6%

Leverage

N.D./EBITDA

3,7

Debt/Equity

0%

Current Ratio

4,6

Quick Ratio

4,4

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium